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Effect of present versus previous 
smoking on non-invasive 
haemodynamics
Manoj Kumar Choudhary  1, Arttu Eräranta  1, Antti J. Tikkakoski1,2, Heidi Bouquin1, 
Elina J. Hautaniemi1, Mika Kähönen1,2, Kalle Sipilä2, Jukka Mustonen1,3 & Ilkka Pörsti1,3
We examined cardiovascular function in 637 volunteers (19–72 years) without antihypertensive 
medication in never smokers (n = 365), present smokers (n = 81) and previous smokers (n = 191, 
median abstinence 10 years). Haemodynamics during passive head-up tilt were recorded using whole-
body impedance cardiography and radial pulse wave analysis. Results were adjusted for age, sex, 
body mass index, LDL cholesterol and alcohol use. Systolic and diastolic blood pressure, heart rate, 
and pulse wave velocity were not different between the groups. Supine aortic reflection times did 
not differ, while upright values were shorter in present versus previous smokers (p = 0.04). Heart rate 
adjusted augmentation index was increased in the supine position in present smokers versus controls 
(p = 0.045), and in present (p < 0.001) and previous (p = 0.031) smokers versus controls in the upright 
position. Supine and upright cardiac output was higher (p ≤ 0.016) and systemic vascular resistance 
lower (p ≤ 0.001) in present versus previous smokers. In spite of the long abstinence, in the upright 
position previous smokers had lower cardiac output (p = 0.032) and higher systemic vascular resistance 
(p = 0.014) than never smokers. In the absence of differences in blood pressure and arterial stiffness, 
present smokers presented with hyperdynamic circulation and enhanced wave reflection compared 
with previous smokers.
Cigarette smoking is one of the most important preventable risk factors for mortality in the Western world1,2, 
accounting for more than 5 million premature deaths globally per year3. Smoking is also the second most com-
mon cause for cardiovascular disease (CVD) after elevated blood pressure (BP)4. According to World Health 
Organisation more than one billion people smoke and the prevalence is continuously rising5. Cardiovascular 
deaths account for >54% of all deaths worldwide, and more than 10% of these deaths are attributed to smoking6.
Smoking predisposes to the progression of atherosclerosis, shown as increased arterial intima-media thickness 
(IMT)7, and higher prevalence of atherosclerotic plaques in autopsy studies8. In a study with 10,914 patients the 
progression of atherosclerosis in current smokers was increased by 50% versus non-smokers, documented using 
measurements of IMT in the carotid artery7. Smoking is also associated with adverse effects on serum lipids9,10, 
insulin resistance11, and activation of the sympathetic nervous system12. Carbon monoxide in the inhaled cig-
arette smoke increases the levels of carboxyhemoglobin, the proportion of which can exceed 7.5% in smokers, 
while the average level in non-smokers is 0.32%13. Although very high levels are uncommon, symptomatic effects 
may occur at carboxyhemoglobin levels of 2.5% or more13.
Controversial reports have been published about the effect of smoking on BP14–17. Gropelli et al. reported that 
smoking causes an acute 15–20 mmHg rise in systolic BP, but the effect starts declining after 10 minutes and can 
be missed if BP is measured more than 30 minutes after smoking15. Some previous reports found that male smok-
ers have increased BP16. In contrast, some studies reported that smokers have lower BP than non-smokers17,18. 
The putative reduction of BP in smokers may be related to lower body weight, while previous smokers often have 
higher body weight and increased BP versus never smokers19. The vasodilator effect of the nicotine metabolite 
cotinine may contribute to the reduction of BP in current smokers20.
Increased arterial stiffness is an independent predictor of CVD21. Many studies have reported that chronic 
smoking is a risk factor for increased arterial stiffness, however, a number of investigations have not found differ-
ences in arterial stiffness between smokers and never smokers22,23. Higher augmentation index (AIx), a marker of 
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wave reflections, has been found to be associated with smoking in several studies14,24–27. Argacha et al. reported 
that acute smoking increases AIx14, while 1-hour exposure to passive smoking was found to increase AIx by 
15.7 percentage points25. Polonia et al. found that AIx was reduced by about 9 percentage points in subjects who 
stopped smoking for 6 months, whereas there was an increase of 1.7 percentage points in those who continued 
smoking28.
Altogether, the effects of smoking on BP and arterial stiffness remain controversial, while increased AIx has 
been documented in many studies but the underlying mechanisms are not well understood. Here we examined 
putative differences in haemodynamics between present, previous, and never smokers. To gain insight about 
the function of the cardiovascular system in the study groups a passive head-up tilt was included in the study 
protocol.
Methods
Participants. All participants were from an ongoing study, the primary aim of which is to examine haemo-
dynamics in subjects with primary and secondary hypertension versus normotensive controls, in both supine 
and upright positions (DYNAMIC study; ClinicalTrails.gov identifier NCT01742702). The total number of all 
enrolled subjects is 1349. The exclusion criteria for the present study were: use of BP-lowering or other medica-
tion with direct cardiovascular influences, secondary hypertension, and history of coronary artery disease, stroke, 
heart failure, valvular heart disease, diabetes, chronic kidney disease, alcohol or substance abuse, psychiatric 
illnesses, or other heart rhythm than sinus.
The participants were enrolled by announcements from the personnel and patients treated at Tampere 
University Hospital, personnel of the University of Tampere, and clients of the Varala Sports Institute and local 
occupational health care providers. Those who agreed to participate were recruited in the order in which they 
contacted the research nurses. All subjects underwent physical examination by a medical doctor and laboratory 
analyses for elevated BP29. The medical history and lifestyle habits were documented along with smoking habits, 
number of cigarettes smoked per day, total smoking duration, and abstinence from smoking in years along with 
family history for CVD. Alcohol consumption was evaluated as standard drinks (~12 grams of absolute alcohol) 
per week.
A total of 637 normotensive subjects and never-treated hypertensive patients, aged 19–72 years, were included 
in the study. They were divided into never smokers (n = 365), present smokers (n = 81) and previous smokers 
(n = 191). Signed informed consent was obtained from all participants. The study complies with the declaration 
of Helsinki, and was approved by the ethics committee of the Tampere University Hospital (study code R06086M) 
and the Finnish Medicines Agency (Eudra-CT registration number 2006-002065-39).
Altogether 247 (39%) of the 637 persons used one or more medications, but the proportions of subjects taking 
some medication in the never smokers, present smokers and previous smokers did not differ (37.8%, 35.8% and 
41.9%, respectively). Seventy-eight female subjects used systemic estrogen, progestin, or their combination (for 
contraception or hormone replacement therapy), and 1 subject used tibolone. Forty-one subjects were taking 
antidepressants, 18 antihistamines, 17 inhaled corticosteroids, 15 statins, 13 proton pump inhibitors, while 22 
euthyroid subjects were on a stable dose of thyroid hormone. The other medications used by the study popula-
tion were hypnotics or sedatives (8), low dose acetylsalicylic acid (6), non-steroidal anti-inflammatory drugs (4), 
antirheumatic agents (4), antiepileptics (3), allopurinol (3), coxibs (3), antipsychotics (2), muscle relaxants (2), 
varenicline (2), antiviral agents (2), paracetamol (1), carbimazole (1), isotretinoin (1), and alendronate (1). One 
physically well and symptomless subject was treated with warfarin due to anti-phospholipid syndrome.
Laboratory analyses. Blood and urine samples were drawn after ~12 hours of fasting. Plasma C-reactive 
protein, sodium, potassium, glucose, cystatin-C, creatinine, triglyceride, and total, high-density lipoprotein 
(HDL) and low-density lipoprotein (LDL) cholesterol concentrations were determined using Cobas Integra 
700/800 (F. Hoffmann-Laroche Ltd, Basel; Switzerland) or Cobas6000, module c501 (Roche Diagnostics, Basel, 
Switzerland), insulin using electrochemiluminescence immunoassay (Cobas e411, Roche Diagnostics), and 
blood cell count by ADVIA 120 or 2120 (Bayer Health Care, Tarrytown, NY, USA). Urine dipstick analysis was 
made by an automated refractometer test (Siemens Clinitec Atlas or Advantus, Siemens Healthcare GmbH, 
Erlangen, Germany). Insulin sensitivity was evaluated by calculating the quantitative insulin sensitivity check 
index (QUICKI)30, and glomerular filtration rate (GFR) was estimated using the CKD-EPI creatinine-cystatin C 
equation31.
Pulse wave analysis. Radial BP and pulse wave were continuously captured from the radial pulsation using 
a tonometric sensor (Colin BP-508T, Colin Medical Instruments Corp., USA), which was secured on the radial 
pulse with a wrist band. The radial BP signal was calibrated twice during each 5 minute-period of recording by 
brachial BP measurements from the contralateral arm. Aortic BP was derived with the SphygmoCor system 
(SpygmoCor PWMxR, AtCor medical, Australia) by means of the validated generalized transfer function32. Left 
ventricular ejection duration, forward wave amplitude (FWA), aortic pulse pressure and reflection time, AIx (aug-
mented pressure/pulse pressure * 100), AIx adjusted to heart rate 75/min (AIx@75), and amplification of pulse 
pressure and systolic pressure (radial pressure/aortic pressure) were determined.
Whole-body impedance cardiography. Beat-to-beat heart rate, stroke volume, cardiac output, and pulse 
wave velocity (PWV) were recorded using whole-body impedance cardiography (CircMonR, JR Medical Ltd., 
Tallinn, Estonia). This method records changes in body electrical impedance during cardiac cycles. Systemic 
vascular resistance was calculated using the BP signal from the radial tonometry and the cardiac index measured 
by the CircMonR device. Systemic vascular resistance was calculated by subtracting normal central venous pres-
sure (4 mmHg) from mean arterial pressure and dividing it by cardiac output. Systemic vascular resistance and 
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cardiac output were related to body surface area and presented as indexes – cardiac index, and systemic vascular 
resistance index (SVRI), respectively. The method and electrode configuration have been previously reported in 
detail33,34.
The stroke volume values measured using CircMonR agree well with 3-dimensional ultrasound35. The supine 
and upright cardiac output values measured with CircMonR agree well with the values measured using thermodi-
lution33,34. The PWV values recorded using CircMonR show very good correlations with values measured using 
ultrasound and the tonometric SphygmoCor method33,34,36.
Experimental protocol. Hemodynamics were recorded in a quiet, temperature-controlled laboratory by 
trained research nurses37,38. Caffeine containing products, smoking or heavy meal were to be avoided for ≥4 
hours, and alcohol consumption for >24 hours prior to the studies. The subjects rested supine on the tilt-table 
with the electrodes placed on body surface, the tonometric sensor on the left radial pulsation, and the oscillomet-
ric brachial cuff to the right upper arm. The left arm with the tonometric wrist sensor was abducted to 90 degrees 
in an arm support, which held the extended arm steady and kept the measurement probes at the heart level both 
supine and upright.
The actual measurement consisted of one 5-minute period supine and second 5-minute period upright. For 
the statistical analyses the mean values of each 1-minute period of recording were calculated. The analyses pro-
vided information about peripheral and central BP and heart rate39, and evaluated large arterial stiffness by meas-
urements of central pulse pressure, FWA, and PWV21,26,40. The transit of forward pressure waves in the arterial 
tree was evaluated by recording the amplification of the systolic pressure and pulse pressure26,41–43, and the influ-
ence of reflected waves by the variables aortic reflection time and AIx27,39,44. Cardiac performance was examined 
by the evaluations of left ventricular ejection duration, stroke volume, and cardiac output, while resistance arterial 
tone was estimated by the calculation of systemic vascular resistance37,38. Previously, the good repeatability and 
reproducibility of the measurement protocol has been demonstrated45.
Statistics. The demographic and laboratory data was analysed using analysis of variance (ANOVA), and the 
homogeneity of variances was tested with the Levene’s test. If variable distribution was skewed, Kruskal-Wallis 
was applied with Mann-Whitney U-test in the post-hoc analyses (Table 1). The Bonferroni correction was applied 
in the post-hoc analyses. Haemodynamic differences between the individual groups were examined in supine and 
upright positions using ANOVA for repeated measures. The analyses were adjusted for age, and for the following 
variables that presented with significant differences between the groups in univariate analyses: sex, body mass 
index (BMI), use of alcohol as standard doses per week, LDL cholesterol; and in analyses concerning PWV also 
Never smoker 
(n = 365) Present smoker (n = 81)
Previous smoker 
(n = 191)
Male/female 164/201 43/38 107/84*
Age (years) 44.2 (0.6) 44.2 (1.3) 46.7 (0.8)
Body mass index (kg/m2) 26.2 (0.2) 26.4 (0.5) 28.0 (0.3)*†
Office systolic BP (mmHg) 139.6 (1.1) 136.9 (2.4) 144.4 (1.6)†
Office diastolic BP (mmHg) 88.7 (0.6) 87.5 (1.4) 91.8 (0.9)*†
Cigarettes/day 0 5 [2–12]* 10 [3–19] *†
Smoking duration (years) 0 15 [7–25]* 10 [3.0–16.5]*†
Total number of cigarettes 0 21900 [7300–87600]* 21900 [4562–79387]*
Smoking abstinence (years) n.a. 0 10 [3–20]†
Alcohol (standard drinks/week) 2.0 [0.0–4.0] 5.5 [2.0–13.0]* 3.0 [1.0–9.5]*†
Estimated GFR (ml/min/1.73 m2) 99.3 (0.8) 98.5 (1.6) 96.4 (1.0)
Hemoglobin (g/L) 143.0 (0.7) 146.0 (1.2) 145.6 (0.8)
Fasting Plasma
  Sodium (mmol/l) 140.4 (0.1) 140.5 (0.2) 140.3 (0.1)
  Potassium (mmol/l) 3.81 (0.01) 3.79 (0.02) 3.81 (0.02)
  C-Reactive Protein (mg/l) 1.5 (0.1) 1.8 (0.3) 2.0 (0.3)
  Triglycerides (mmol/l) 0.97 [0.68–1.34] 1.18 [0.86–1.75]* 1.18 [0.86–1.58]*
  HDL cholesterol (mmol/l) 1.60 (0.02) 1.52 (0.04) 1.54 (0.03)
  LDL cholesterol (mmol/l) 2.91 (0.05) 3.21 (0.11)* 3.26 (0.07)*
  Glucose (mmol/l) 5.39 (0.03) 5.54 (0.08) 5.54 (0.04)*
  Insulin (mU/l) 9.04 (1.15) 8.86 (0.84) 9.02 (0.47)
  QUICKI 0.361 (0.002) 0.355 (0.004) 0.352 (0.003)#
Table 1. Basic Clinical Characteristics and Laboratory Results. Results shown as mean (standard error of mean) 
or median [25th to 75th percentile]; n.a., not applicable; GFR, glomerular filtration rate (CKD-EPI cystatin-C 
creatinine formula); QUICKI, quantitative insulin sensitivity check index; *P < 0.05 vs. never smoker; †P < 0.05 
vs. present smoker (#p = 0.059 vs. never smoker).
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for systolic BP. The analyses were not adjusted for triglycerides, since increased plasma triglyceride concentration 
may represent a true effect of smoking on plasma lipids9,10.
Linear regression analysis with the enter method was employed to examine the effect of gender and the hae-
modynamic variables on the level of AIx in supine and upright positions (Table 2), while stepwise linear regres-
sion analysis was employed to examine the associations of demographic, laboratory, and haemodynamic variables 
with AIx (Supplementary Table). For these analyses the skewed distribution of PWV and triglycerides was cor-
rected by lg10-transformation, while alcohol consumption was treated as a series of discrete variables that were 
assigned a score of either 0 or 1; cut-points for women 0, 1–7, 8–14, and above 15 doses per week; for men 0, 1–14, 
15–24, and above 25 doses per week, according to the prevailing Finnish Guidelines46. Spearman’s correlations 
(rS) were calculated, as appropriate. The results were presented as means and standard errors of the mean (SEM) 
or median [25th to 75th percentile], and p < 0.05 was considered statistically significant. SPSS version 22.0 (IBM 
SPSS Statistics, Armonk, NY, USA) was used for the statistics.
Results
Study population and laboratory values. The previous smokers had slightly lower proportion of female 
subjects, while mean age between the study groups did not differ (Table 1). BMI was higher in previous smokers 
compared to never- and present smokers. In the office systolic BP was ~6 mmHg higher in previous smokers 
versus present smokers, while diastolic BP was higher in previous smokers compared to never and present smok-
ers. The median number of consumed cigarettes was 21900 in present and previous smokers, while the median 
abstinence from smoking in previous smokers was 10 years. The weekly intake of alcohol was higher in present 
and previous smokers than in never smokers, with slightly higher alcohol intake was also observed in the present 
versus previous smokers, but the average values were well within the limits of moderate drinking in all groups 
(Table 1). LDL cholesterol level was higher in present and previous smokers, while triglyceride level was higher 
in present and previous smokers when compared with never smokers. Fasting plasma glucose was slightly higher 
in the previous smokers versus the never smokers, while QUICKI values were not significantly different between 
the groups (Table 1).
Haemodynamic effects associated with present and previous smoking. In unadjusted analyses, 
radial and aortic systolic and diastolic BP was higher in previous smokers than present smokers and never smok-
ers (Fig. 1A–D). However, when adjusted for age, sex, BMI, LDL cholesterol, and use of alcohol, the differences in 
BP values between the groups were not significant (Supplementary Fig. A,B). In the text below, only the results of 
the adjusted analyses are being referred to, while the unadjusted statistics are also shown in the figures.
Aortic pulse pressure was not different between the individual groups in either supine or upright position 
(Fig. 2A). Supine aortic-to-radial amplification of pulse pressure (Fig. 2B) and systolic pressure (Fig. 2C) showed 
differences in adjusted ANOVA (p = 0.035 and 0.022, respectively), but the differences between individual study 
groups were not significant. In the upright position, pulse pressure amplification did not differ between the groups 
(Fig. 2B), while amplification of systolic BP was reduced in the present (p = 0.002) and previous (p = 0.009) smok-
ers versus never smokers (Fig. 2C). No significant differences were found in PWV between the individual study 
groups in analyses adjusted for age, sex, BMI, LDL cholesterol, use of alcohol, and systolic BP (Fig. 2D).
Augmentation index b beta
95% confidence interval for b
P valueLower Upper
Supine, R2 = 0.609, p < 0.001
  Constant 7.069 −16.932 31.069 0.563
  Male sex −6.936 −0.291 −8.423 −5.450 <0.001
  Systemic vascular resistance index 0.005 0.245 0.003 0.007 <0.001
  Lg10 of pulse wave velocity 36.760 0.290 28.668 44.851 <0.001
  Stroke index 0.230 0.138 0.106 0.353 <0.001
  Heart rate −0.232 −0.187 −0.337 −0.127 <0.001
  Ejection duration 0.093 0.154 0.048 0.138 <0.001
  Aortic reflection time −0.361 −0.474 −0.406 −0.317 <0.001
Upright, R2 = 0.733, p < 0.001
  Constant −10.109 −28.205 7.987 0.273
  Male sex −1.867 −0.076 −3.286 −0.448 0.010
  Systemic vascular resistance index 0.002 0.086 0.001 0.003 0.005
  Lg10 of pulse wave velocity 21.012 0.161 14.842 27.183 <0.001
  Stroke index −0.127 −0.047 −0.295 0.041 0.137
  Heart rate −0.089 −0.080 −0.167 −0.010 0.027
  Ejection duration 0.328 0.600 0.292 0.365 <0.001
  Aortic reflection time −0.532 −0.454 −0.585 −0.478 <0.001
Table 2. Linear regression analysis with the enter method: hemodynamic variables and sex as explanatory 
variables for augmentation index. Variables used: Systemic vascular resistance index, the common logarithm of 
PWV, heart rate, stroke volume index. Lg10, the common logarithm; n = 631 subjects.
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Neither heart rate (Fig. 3A) nor ejection duration (Fig. 3B) differed between the study groups. Both supine 
and upright FWA was lower in present smokers than in never smokers (p ≤ 0.042) (Fig. 3C). Supine aortic reflec-
tion time was not different between the groups, but was shorter in present smokers than in previous smokers 
(p = 0.049) during upright position (Fig. 3D).
ANOVA of AIx in the supine position indicated differences (p = 0.020) but the deviations between individ-
ual groups were not significant (Fig. 3E). However, heart rate adjusted AIx@75 was increased (p = 0.045) in the 
supine position in present smokers versus never smokers (Fig. 3F). In the upright position, both AIx and AIx@75 
were higher in present smokers than in never smokers (p ≤ 0.003), while AIx@75 was also higher in present 
smokers than in previous smokers (p = 0.031, Fig. 3E,F, Supplementary Fig. C).
Supine stroke index was higher in present smokers when compared with never smokers (p = 0.009) and pre-
vious smokers (p = 0.001), while upright values were higher in present than in previous smokers (p = 0.044) 
(Fig. 4A). Cardiac index was increased in present smokers versus previous smokers both supine and upright 
(p ≤ 0.016), while cardiac index was lower in previous smokers than in never smokers in the upright position 
(p = 0.032, Fig. 4B, Supplementary Fig. D). When compared with never smokers, supine but not upright SVRI 
was lower in present smokers (p = 0.041), while upright but not supine SVRI was increased in the previous smok-
ers (p = 0.014). Both supine and upright SVRI was higher in previous smokers versus present smokers (p ≤ 0.001) 
(Fig. 4C).
Results of analyses in subjects not taking medications. Altogether 227 never smokers, 52 present smokers, and 
111 previous smokers were without any regular medications. In these subjects, supine AIx@75 was not differ-
ent between never smokers and present smokers (p = 0.133), while the main findings showing increased AIx 
Figure 1. Supine and upright radial systolic (A) and diastolic (B) blood pressure, and aortic systolic (C) and 
diastolic (D) blood pressure in never smokers (n = 365), present smokers (n = 81), and previous smokers 
(n = 191); mean ± standard error of the mean; ANOVA results from unadjusted analyses (plain text) and from 
analyses adjusted for age, sex, BMI, LDL cholesterol, and alcohol use (italic) are shown (see Methods).
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(p = 0.007) and AIx@75 (p = 0.005) in the upright position in the present smokers versus never smokers were 
still detected. The differences in supine stroke index (p = 0.007) and cardiac index (p = 0.038), and upright aortic 
reflection time (p = 0.038) remained significant between present smokers and previous smokers. However, some 
deviations were found when compared with the whole study population: Supine SVRI was not higher in previous 
smokers than present smokers (p = 0.083), but was higher in previous smokers than in never smokers (p = 0.013). 
Supine stroke index did not differ between present smokers and never smokers (p = 0.213), while upright stroke 
index did not differ between present smokers and previous smokers (p = 0.063). Upright cardiac index did not 
show differences between the groups (previous smokers versus never smokers p = 0.074), while supine and 
upright SVRI were no more different between present smokers and never smokers (p = 1.000 and p = 1.000, 
respectively). Supine pulse pressure amplification did not differ (p = 0.072), while supine systolic amplification 
was lower in previous smokers than never smokers (p = 0.022).
Multivariate analysis about the factors associated with augmentation index. Present smoking 
increased AIx although it did not reduce heart rate, elevate PWV, or increase systemic vascular resistance, i.e. 
induce changes in the variables that are most often related to an increase in AIx36,39,40,47. Therefore, linear regres-
sion analysis was performed to examine the relations of the haemodynamic variables with AIx (Table 2). Due to 
its powerful confounding, sex was included in the model36,38,39,48. These analyses showed that sex and the hemod-
ynamic variables SVRI, PWV, heart rate, ejection duration, and aortic reflection time were significant explanatory 
variables for AIx (p ≤ 0.027) in both supine and upright positions. Stroke index was a significant explanatory var-
iable for AIx in supine (0 < 0.001) but not in the upright position (p = 0.137). The overall R2 values for the model 
were 0.609 in the supine and 0.733 in the upright position.
Figure 2. Supine and upright aortic pulse pressure (A), pulse pressure amplification (B), and systolic 
amplification (C), and supine pulse wave velocity (D) in never smokers (n = 365), present smokers (n = 81), and 
previous smokers (n = 191); mean ± standard error of the mean; ANOVA results from unadjusted (plain text) 
and adjusted (italic) analyses are shown.
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Additionally, the relations between demographic variables, smoking status, alcohol intake, laboratory varia-
bles, haemodynamic variables, and AIx were examined by the use of regression analysis (Supplementary Table). 
These analyses also showed that the variables that could explain an increase in AIx in present smokers, i.e. ele-
vated supine stroke index and shorter upright aortic reflection time, were independently associated with AIx. 
Moreover, present smoking was related with elevated AIx both supine and upright.
Figure 3. Heart rate (A), ejection duration (B), forward wave amplitude (C), aortic reflection time (D), 
augmentation index (E), and augmentation index adjusted to heart rate of 75 beats per minute (F) in never 
smokers (n = 365), present smokers (n = 81), and previous smokers (n = 191); mean ± standard error of the 
mean; ANOVA results from unadjusted (plain text) and adjusted (italic) analyses are shown.
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Discussion
Previous reports about the influence of smoking on the level of BP and arterial stiffness have been contradic-
tory14,15,17,22,49. Here we examined the haemodynamic effects of smoking using non-invasive recordings of central 
BP, arterial stiffness, cardiac performance, and systemic vascular resistance. A passive head-up tilt was included, 
as possible changes in haemodynamics may become more apparent during upright posture37,38,50. Many studies 
have found that smoking increases AIx, but our findings for the first time suggest that AIx may be higher in smok-
ers due to an increase in cardiac stroke volume and shortening of the aortic reflection time.
Figure 4. Stroke index (A), cardiac index (B), and systemic vascular resistance index (C) in never smokers 
(n = 365), present smokers (n = 81), and previous smokers (n = 191); mean ± standard error of the mean; 
ANOVA results from unadjusted (plain text) and adjusted (italic) analyses are shown.
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Smoking has not been associated with consistent effects on BP14,15,17. In the present study, higher BP in pre-
vious smokers was attributed to the confounding effects of age, sex, BMI, use of alcohol, and LDL cholesterol. 
In the adjusted analyses, neither present nor previous smoking influenced BP, corresponding to some previous 
reports17,51. This emphasises that the confounding factors must be carefully taken into account in all analyses52. 
Quitting smoking predisposes to increases in weight and BP19, while the risk of hypertension increases in previ-
ous smokers with increasing years of abstinence53.
Smokers may have higher serum cholesterol and triglyceride levels than never smokers54,55. Insulin resistance 
in smokers can alter lipid and lipoprotein metabolism56. Previously, smokers had higher triglyceride levels than 
never smokers in the absence of differences in LDL cholesterol10. Smokers also exhibited higher postprandial 
increases in triglyceride levels than non‐smokers, indicating impaired lipolytic removal capacity9. Altogether, 
smoking promotes atherosclerosis via several mechanisms including changes in blood clotting and lipids, 
endothelial function, insulin sensitivity, and autonomic tone7,11–13,54,57. In our study, the present smokers had 
higher plasma concentrations of LDL cholesterol and triglycerides than never smokers. In previous smokers LDL 
cholesterol and triglycerides were also higher than in never smokers, probably due to the increased BMI11,58.
Increased PWV is a strong predictor of CVD mortality independent of the level of BP21. Early stages of ather-
osclerosis do not influence the stiffness of the arterial wall, while advanced calcified plaques are associated with 
increased arterial stiffness59. Previously, carotid IMT and plaques were not associated with aortic PWV when 
adjusted for the confounders age, gender, BP, smoking, and diabetes60,61. Thus, aortic stiffness does not predict the 
severity of carotid atherosclerosis60,61. The influence of smoking on PWV remains controversial, and all investiga-
tions have not found differences in arterial stiffness between smokers and non-smokers22,23. In the present study, 
PWV did not differ between present smokers and never smokers, while PWV was highest in previous smokers. 
However, when adjusted for the above confounders, PWV did not differ between the study groups.
The level of AIx, a marker of wave reflections, is influenced by arterial stiffness, heart rate, ventricular ejection 
duration, body height, BP, systemic vascular resistance, and stroke volume36,37,39,40,47. Previous reports have shown 
that acute, chronic and passive smoking are associated with increased AIx14,24–28. However, this has not been 
attributed to the variables that are known to increase the level of augmentation, like lower heart rate, increased 
arterial stiffness, or higher systemic vascular resistance24,26,36,48,49,62 In our study present smokers had higher 
upright AIx, and higher supine and upright AIx@75, in the absence of changes in BP, heart rate, ejection duration, 
PWV, and systemic vascular resistance that could explain an increase in AIx. However, present smokers presented 
with increased stroke index in supine and upright positions, and decreased upright aortic reflection time versus 
previous smokers. Both of these factors are associated with higher AIx36,39,44. In order to elucidate the haemod-
ynamic determinants of wave reflection, we performed regression analyses of the explanatory variables of AIx. 
These analyses confirmed that stroke index was an independent determinant of supine AIx, while shorter aortic 
reflection time was associated with higher AIx both supine and upright. Corresponding to a previous report 
showing that smoking cessation is associated with reductions in AIx28, the level did not differ between previous 
smokers and never smokers.
Nicotine in tobacco smoke stimulates the sympathetic nervous system12,63. In male smokers, nicotine elevated 
metabolic rate at rest, and increased energy expenditure during light exercise64. The present results showed that 
smoking was associated with increased stroke index in the absence of changes in heart rate. Thus, smoking stim-
ulated the contractile properties of the heart, probably via mechanisms that increase the metabolic rate64 and 
elevate the sympathetic tone12,63. Increased stroke index was also translated to higher cardiac output in present 
smokers versus previous smokers. Previously, current smokers had higher cardiac output than never smokers in 
an ultrasound-based evaluation18.
We found that systemic vascular resistance in the present smokers was lower than in never smokers in the 
supine position, and lower than in previous smokers in both supine and upright positions. Such haemodynamic 
changes may be related to the impaired oxygen transport properties of blood during smoking, as carbon monox-
ide in cigarette smoke increases the levels of carboxyhemoglobin in red cells13. Carbon monoxide has also vaso-
dilatory properties65. Corresponding to our findings, male smokers presented with vasodilatation in the palmar 
microvasculature when compared with non-smokers51.
Smokers have twice the death rate versus never smokers due to coronary events, while in patients with cor-
onary heart disease the risk of mortality is reduced after 2 years of abstinence from smoking66. There is some 
immediate reduction in CVD risk after smoking cessation41, but the period of the remaining increase in risk 
remains unclear67,68. In the present study, upright cardiac output was reduced and systemic vascular resistance 
was increased in previous smokers versus never smokers. These findings after 10 years of abstinence may repre-
sent persistent changes in haemodynamics after the withdrawal of the 10-year-long influence of tobacco smoke 
on cardiovascular regulation.
In contrast to the increase in PWV and AIx with increasing age, aortic reflection time is only moderately short-
ened during ageing44. In the present study, age correlated strongly with PWV (rS = 0.67) and AIx (rS = 0.57 supine, 
rS = 0.52 upright), but only moderately with aortic reflection time (rS = −0.31, rS = −0.23 upright) (p < 0.001 
for all). In concert with earlier findings26, our results showed that upright aortic reflection time was faster in the 
present smokers than previous smokers. Shorter aortic reflection time provides a possible explanation for the dif-
ference in upright AIx@75 between these groups. Although upright AIx and AIx@75 were higher in the present 
smokers than in never smokers, neither upright aortic reflection time nor upright stroke index differed between 
these groups. The possibility remains that statistically insignificant changes in the above variables resulted in 
higher wave reflections in the present smokers. Supporting this view, the relation of stroke index to aortic reflec-
tion time was higher in present smokers than in never smokers both supine and upright (0.334 ± 0.007 versus 
0.314 ± 0.03 ml/m2/ms, p = 0.009; 0.248 ± 0.004 versus 0.237 ± 0.002 ml/m2/ms, p = 0.021; respectively).
Aortic-to-brachial pulse pressure amplification reflects arterial compliance in the upper limb, showing 
reduced values with ageing42. Although reduced pulse pressure amplification has been suggested in smokers 
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versus non-smokers41,43, the present results did not show differences in this variable between present smokers and 
never smokers. However, previous smokers presented with impaired amplification of supine and upright systolic 
pressure. This suggests prevailing differences in the circulation from the aorta to the upper limb in previous 
smokers, although these findings may also be attributed to the less favourable metabolic profile in this group. 
Furthermore, upright systolic pressure amplification was impaired in the present smokers versus never smokers. 
The probable explanation for this is increased augmentation that reduces systolic pressure amplification26,43.
This study has some limitations. The results should be interpreted cautiously, as non-invasive measurements 
were used to evaluate cardiac output, and this requires mathematical processing and simplification of physiol-
ogy33. However, invasive haemodynamic measurements cannot be performed without a clear clinical indication. 
The present methods have been validated against invasive methods, 3-dimensional ultrasound, and tonometric 
measurements of PWV32,33,35,36. The supine and upright recordings lasted in total for 10 minutes, and this gives 
a rather narrow window of observation for the study of haemodynamics in humans. The present cross-sectional 
design does not allow conclusions about causal relationship, and the present findings should be confirmed in 
follow-up studies. Although all subjects using antihypertensive medications and other medications with direct 
influences on haemodynamics were excluded, the other medications used by 39% of the study population may 
have influenced the results. However, the principal findings of the study remained very similar when all subjects 
taking regular medications were excluded from the analyses.
In conclusion, the present results showed that smoking status had a significant influence on the regulation of 
cardiac output and systemic vascular resistance in the absence of changes in BP and arterial stiffness. The present 
smokers presented with hyperdynamic circulation and enhanced wave reflection when compared with previous 
smokers, while the previous smokers had increased upright systemic vascular resistance and lower cardiac output 
when compared with never smokers. Finally, our findings suggest that increased AIx in present smokers may be 
attributed to an increase in stroke volume and shortening of the aortic reflection time.
Data Availability
Analyses and generated datasets during the current study are not available publicly as our clinical database con-
tains several indirect identifiers and the informed consent obtained does not allow publication of individual 
patient data. The datasets are available from the corresponding author on reasonable request.
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